Evidence map›Paper›PMID 24599325›Full record

ArticlePloS one2014

Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy.

Justin T Clark, Meredith R Clark, Namdev B Shelke, Todd J Johnson, Eric M Smith, Andrew K Andreasen, Joel S Nebeker, Judit Fabian, David R Friend, Patrick F Kiser

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 96 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  10. Review
  11. Article
  12. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Use of simulated vaginal and menstrual fluids to modelInternational journal of pharmaceutics: X · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Justin T ClarkDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
Meredith R ClarkCONRAD, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Arlington, Virginia, United States of America.
Namdev B ShelkeDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
Todd J JohnsonDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
Eric M SmithDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
Andrew K AndreasenDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
Joel S NebekerDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
Judit FabianDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America.
David R FriendCONRAD, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Arlington, Virginia, United States of America.
Patrick F KiserDepartment of Bioengineering, University of Utah, Salt Lake City, Utah, United States of America; Department of Biomedical Engineering, Northwestern University, Evanston IL, United States of America.
University of Utah · USEastern Virginia Medical School · USNorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HIV/AIDS pandemic and its impact on women prompt the investigation of prevention strategies to interrupt sexual transmission of HIV. Long-acting drug delivery systems that simultaneously protect womenfrom sexual transmission of HIV and unwanted pregnancy could be important tools in combating the pandemic. We describe the design, in silico, in vitro and in vivo evaluation of a dual-reservoir intravaginal ring that delivers the HIV-1 reverse transcriptase inhibitor tenofovir and the contraceptive levonorgestrel for 90 days. Two polyether urethanes with two different hard segment volume fractions were used to make coaxial extruded reservoir segments with a 100 µm thick rate controlling membrane and a diameter of 5.5 mm that contain 1.3 wt% levonorgestrel. A new mechanistic diffusion model accurately described the levonorgestrel burst release in early time points and pseudo-steady state behavior at later time points. As previously described, tenofovir was formulated as a glycerol paste and filled into a hydrophilic polyurethane, hollow tube reservoir that was melt-sealed by induction welding. These tenofovir-eluting segments and 2 cm long coaxially extruded levonorgestrel eluting segments were joined by induction welding to form rings that released an average of 7.5 mg tenofovir and 21 µg levonorgestrel per day in vitro for 90 days. Levonorgestrel segments placed intravaginally in rabbits resulted in sustained, dose-dependent levels of levonorgestrel in plasma and cervical tissue for 90 days. Polyurethane caps placed between segments successfully prevented diffusion of levonorgestrel into the tenofovir-releasing segment during storage.Hydrated rings endured between 152 N and 354 N tensile load before failure during uniaxial extension testing. In summary, this system represents a significant advance in vaginal drug delivery technology, and is the first in a new class of long-acting multipurpose prevention drug delivery systems.

Indexed as

Contraceptive Devices, FemalePregnancy, UnwantedAlgorithmsAnimalsContraceptive Agents, FemaleDrug Delivery SystemsElasticityFemaleHIV InfectionsHumansLevonorgestrelModels, TheoreticalPolyurethanesPregnancyRabbitsTensile StrengthContraceptive Agents, FemaleLevonorgestrelpolyetherurethanePolyurethanes

Identifiers

PMID24599325
PMCPMC3943718
OpenAlexW1988491543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.